BUNIA, DEMOCRATIC REPUBLIC OF THE CONGO / RankWire.AI / – The World Health Organization announced that 80% of recent Ebola infections in eastern Congo originate from unidentified transmission pathways. These individuals did not appear on contact lists associated with previously confirmed cases. Health teams only identified many of these cases after symptoms appeared, testing was conducted, or deaths occurred, prompting new alerts. WHO emphasized that this surveillance gap remains among the most critical issues in controlling the outbreak. The current outbreak involves the Bundibugyo virus, a rare strain of Ebola.

According to the latest national report, Congolese health officials documented 2,011 confirmed cases and 754 fatalities up to July 13. The most recent daily update recorded 54 new cases and 28 deaths. Authorities have placed 753 patients in isolation, with 366 individuals having recovered. Response teams are monitoring 67.4% of identified contacts in Ituri, North Kivu, and Haut-Uele. Typically, contact monitoring continues for 21 days after the last known exposure.
Tracing contacts enables health workers to observe exposed individuals and promptly arrange testing when symptoms develop. WHO indicated that 92.3% of the 430 investigated deaths through July 5 occurred either in community settings or before hospital admission. This suggests delays in detection, referral, isolation, and access to healthcare. Ebola transmits through direct contact with infected blood or bodily fluids. The disease can also spread via contaminated objects or contact with someone who has died from the infection.
Outbreak spreads across five Congolese provinces
Ituri remains the epicenter, with 1,808 confirmed cases and 631 deaths. The province has reported infections across 26 of its 36 health zones. North Kivu has recorded 182 cases and 106 deaths across 11 zones. South Kivu reported three cases and one death. Haut-Uele reported 14 cases and 13 deaths, while Tshopo had four cases and three deaths. In total, 45 out of 140 health zones across these five provinces have documented infections.
Uganda reported 20 confirmed cases and two deaths by July 14, with 17 recoveries. The last confirmed case in Uganda was recorded on June 21. Of these cases, 15 had links to travel in Congo, and five involved local transmission. Authorities found no evidence of community spread within Uganda. Additionally, health officials traced imported cases involving travelers or aid workers leaving affected areas in Congo. These cases led to isolation, specialized treatment, and contact monitoring in the destination countries.
Enhanced diagnostics and treatment research efforts underway
Bundibugyo virus currently lacks a licensed vaccine or approved specific therapy. Medical management emphasizes rapid diagnosis, isolation, fluids, oxygen, electrolyte replacement, and supportive care. WHO added its first molecular diagnostic test for the virus to the Emergency Use Listing on July 2. This test detects viral genetic material in blood samples. Testing capacity across affected provinces has expanded to 10 sites, with a daily testing capacity exceeding 2,000. Researchers have launched the PARTNERS trial to assess the efficacy of remdesivir and the monoclonal antibody MBP134.
Congolese authorities, WHO, and Africa CDC are collaboratively overseeing surveillance, laboratory testing, clinical care, safe burials, contact tracing, and community engagement. Challenges include insecurity, displacement, and high movement through mining and trade routes, which have disrupted access to some communities and health facilities. WHO stated that it has received approximately 40% of a $115 million funding appeal for the response efforts. Officials continue prioritizing early detection and swift isolation, as most new cases still originate outside known transmission chains.
